{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:41:04Z","timestamp":1790736064360,"version":"4.1.0"},"reference-count":148,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Gram positive pathogens are a significant cause of healthcare-associated infections, with Staphylococci and Enterococci being the most prevalent ones. Vancomycin, a last resort glycopeptide, is used to fight these bacteria but the emergence of resistance against this drug leaves some patients with few therapeutic options. To counter this issue, new generations of antibiotics have been developed but resistance has already been reported. In this article, we review the strategies in place or in development to counter vancomycin-resistant pathogens. First, an overview of traditional antimicrobials already on the market or in the preclinical or clinical pipeline used individually or in combination is summarized. The second part focuses on the non-traditional antimicrobials, such as antimicrobial peptides, bacteriophages and nanoparticles. The conclusion is that there is hitherto no substitute equivalent to vancomycin. However, promising strategies based on drugs with multiple mechanisms of action and treatments based on bacteriophages possibly combined with conventional antibiotics are hoped to provide treatment options for vancomycin-resistant Gram-positive pathogens.<\/jats:p>","DOI":"10.3390\/antibiotics10091116","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T21:38:12Z","timestamp":1631828292000},"page":"1116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-8715","authenticated-orcid":false,"given":"Benjamin","family":"Ba\u00ebtz","sequence":"first","affiliation":[{"name":"Normandie Univ., UNICAEN U2RM-Stress and Virulence, Esplanade de la paix, 14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Boudrioua","sequence":"additional","affiliation":[{"name":"Normandie Univ., UNICAEN U2RM-Stress and Virulence, Esplanade de la paix, 14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hartke","sequence":"additional","affiliation":[{"name":"Normandie Univ., UNICAEN U2RM-Stress and Virulence, Esplanade de la paix, 14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-3218","authenticated-orcid":false,"given":"Caroline","family":"Giraud","sequence":"additional","affiliation":[{"name":"Normandie Univ., UNICAEN U2RM-Stress and Virulence, Esplanade de la paix, 14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"ref_1","unstructured":"O\u2019Neill, J. (2016). Tackling Drug-Resistant Infections Globally: Final Report and Recommendations."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40258-018-0451-1","article-title":"A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study","volume":"17","author":"Touat","year":"2019","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable Deaths and Disability-Adjusted Life-Years Caused by Infections with Antibiotic-Resistant Bacteria in the EU and the European Economic Area in 2015: A Population-Level Modelling Analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","article-title":"Critical Analysis of Antibacterial Agents in Clinical Development","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/d41586-020-02418-x","article-title":"The Antibiotic Paradox: Why Companies Can\u2019t Afford to Create Life-Saving Drugs","volume":"584","author":"McKenna","year":"2020","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1038\/s41467-019-11303-9","article-title":"Designing Development Programs for Non-Traditional Antibacterial Agents","volume":"10","author":"Rex","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: A History","volume":"42","author":"Levine","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The Rise of the Enterococcus: Beyond Vancomycin Resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_10","unstructured":"Gilmore, M.S., Clewell, D.B., Ike, Y., and Shankar, N. (2014). Enterococcal Infection\u2014Treatment and Antibiotic Resistance. Enterococci: From Commensals to Leading Causes of Drug Resistant Infection, Massachusetts Eye and Ear Infirmary."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1128\/jcm.26.6.1216-1218.1988","article-title":"Recovery of Resistant Enterococci during Vancomycin Prophylaxis","volume":"26","author":"Kaplan","year":"1988","journal-title":"J. Clin. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM198807213190307","article-title":"Plasmid-Mediated Resistance to Vancomycin and Teicoplanin in Enterococcus faecium","volume":"319","author":"Leclercq","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0924-8579(00)00300-9","article-title":"Acquired and Intrinsic Glycopeptide Resistance in Enterococci","volume":"16","author":"Gholizadeh","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/BF01967563","article-title":"Structure, Biochemistry and Mechanism of Action of Glycopeptide Antibiotics","volume":"8","author":"Reynolds","year":"1989","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_15","unstructured":"Schaechter, M. (2009). Desk Encyclopedia of Microbiology, Elsevier\/AP. [2nd ed.]."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jmb.2008.10.026","article-title":"Crystal Structures of the Complexes between Vancomycin and Cell-Wall Precursor Analogs","volume":"385","author":"Nitanai","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_17","unstructured":"ECDC (2021, January 01). Antimicrobial Resistance in the EU\/EEA (EARS-Net)\u2014Annual Epidemiological Report for 2019. Available online: ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2019."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/430909","article-title":"Comparison of Mortality Associated with Vancomycin-Resistant and Vancomycin-Susceptible Enterococcal Bloodstream Infections: A Meta-Analysis","volume":"41","author":"DiazGranados","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s12602-019-09618-6","article-title":"The Increasing Issue of Vancomycin-Resistant Enterococci and the Bacteriocin Solution","volume":"12","author":"Reinseth","year":"2020","journal-title":"Probiot. Antimicrob. Proteins"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drup.2018.10.002","article-title":"Update on Prevalence and Mechanisms of Resistance to Linezolid, Tigecycline and Daptomycin in Enterococci in Europe: Towards a Common Nomenclature","volume":"40","author":"Bender","year":"2018","journal-title":"Drug Resist. Updates"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11908-019-0680-y","article-title":"Novel Strategies for the Management of Vancomycin-Resistant Enterococcal Infections","volume":"21","author":"Contreras","year":"2019","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/phar.1922","article-title":"Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence","volume":"37","author":"Yim","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/jac\/dkg249","article-title":"Linezolid in Vitro: Mechanism and Antibacterial Spectrum","volume":"51","author":"Livermore","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1128\/AAC.00131-06","article-title":"The Cfr RRNA Methyltransferase Confers Resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A Antibiotics","volume":"50","author":"Long","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cit616","article-title":"Tedizolid for the Management of Human Infections: In Vitro Characteristics","volume":"58","author":"Locke","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/jac\/dkv438","article-title":"Detection in Italy of Two Clinical Enterococcus faecium Isolates Carrying Both the Oxazolidinone and Phenicol Resistance Gene optrA and a Silent Multiresistance Gene cfr: Table 1","volume":"71","author":"Brenciani","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/acsinfecdis.7b00251","article-title":"Antibiotic Resistance ABC-F Proteins: Bringing Target Protection into the Limelight","volume":"4","author":"Sharkey","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s10096-017-2934-7","article-title":"Linezolid-Resistant Enterococci in Polish Hospitals: Species, Clonality and Determinants of Linezolid Resistance","volume":"36","author":"Gawryszewska","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.coph.2010.06.006","article-title":"Resistance or Decreased Susceptibility to Glycopeptides, Daptomycin, and Linezolid in Methicillin-Resistant Staphylococcus aureus","volume":"10","author":"Nannini","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jgar.2017.10.018","article-title":"The Emerging Problem of Linezolid-Resistant Enterococci","volume":"13","author":"Bi","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13756-016-0131-6","article-title":"Emergence of Linezolid- and Vancomycin-Resistant Enterococcus faecium in a Department for Hematologic Stem Cell Transplantation","volume":"5","author":"Krull","year":"2016","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jgar.2020.05.003","article-title":"Low Prevalence of Combined Linezolid- and Vancomycin-Resistant Enterococcus faecium from Hospital Admission Screening in an Endemic Region in Germany","volume":"22","author":"Heininger","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkg352","article-title":"Antibiotic Activity against Urinary Tract Infection (UTI) Isolates of Vancomycin-Resistant Enterococci (VRE): Results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS)","volume":"52","author":"Zhanel","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/IDR.S54125","article-title":"Vancomycin-Resistant Enterococcal Infections: Epidemiology, Clinical Manifestations, and Optimal Management","volume":"8","author":"Crank","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, X., Wang, Y., Schwarz, S., Shen, J., and Xia, X. (2018). Intracellular Accumulation of Linezolid and Florfenicol in OptrA-Producing Enterococcus faecalis and Staphylococcus aureus. Molecules, 23.","DOI":"10.3390\/molecules23123195"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bbamem.2006.02.009","article-title":"Mode of Action of the New Antibiotic for Gram-Positive Pathogens Daptomycin: Comparison with Cationic Antimicrobial Peptides and Lipopeptides","volume":"1758","author":"Straus","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Chuang, Y.-C., Wang, J.-T., Lin, H.-Y., and Chang, S.-C. (2014). Daptomycin versus Linezolid for Treatment of Vancomycin-Resistant Enterococcal Bacteremia: Systematic Review and Meta-Analysis. BMC Infect. Dis, 14.","DOI":"10.1186\/s12879-014-0687-9"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jac\/dku386","article-title":"Ceftobiprole and Ampicillin Increase Daptomycin Susceptibility of Daptomycin-Susceptible and -Resistant VRE","volume":"70","author":"Werth","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"a026997","DOI":"10.1101\/cshperspect.a026997","article-title":"Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci","volume":"6","author":"Miller","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.12948","article-title":"Mechanisms of Drug Resistance: Daptomycin Resistance","volume":"1354","author":"Tran","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26925","DOI":"10.1073\/pnas.1916037116","article-title":"Antimicrobial Sensing Coupled with Cell Membrane Remodeling Mediates Antibiotic Resistance and Virulence in Enterococcus faecalis","volume":"116","author":"Khan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1128\/AAC.00098-14","article-title":"Defining Daptomycin Resistance Prevention Exposures in Vancomycin-Resistant Enterococcus faecium and E. faecalis","volume":"58","author":"Werth","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"16900","DOI":"10.1073\/pnas.1208037109","article-title":"Structural Basis for TetM-Mediated Tetracycline Resistance","volume":"109","author":"Franckenberg","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1128\/AAC.00547-15","article-title":"The Ribosomal S10 Protein Is a General Target for Decreased Tigecycline Susceptibility","volume":"59","author":"Beabout","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1089\/mdr.2019.0346","article-title":"A Nosocomial Cluster of Tigecycline- and Vancomycin-Resistant Enterococcus faecium Isolates and the Impact of RpsJ and Tet(M) Mutations on Tigecycline Resistance","volume":"26","author":"Bender","year":"2020","journal-title":"Microb. Drug Resist."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1099\/jmm.0.000993","article-title":"Tigecycline and Inducible Clindamycin Resistance in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus from Terengganu, Malaysia","volume":"68","author":"Hamzah","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.diagmicrobio.2016.10.009","article-title":"Surveillance of Tedizolid Activity and Resistance: In Vitro Susceptibility of Gram-Positive Pathogens Collected over 5 Years from the United States and Europe","volume":"87","author":"Bensaci","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1021\/acs.bioconjchem.9b00739","article-title":"Silver Nanoparticle Conjugated Star PCL-b-AMPs Copolymer as Nanocomposite Exhibits Efficient Antibacterial Properties","volume":"31","author":"Zhen","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.1021\/ja0359761","article-title":"D-Ala-D-Lac Binding Is Not Required for the High Activity of Vancomycin Dimers against Vancomycin Resistant Enterococci","volume":"125","author":"Jain","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1039\/c0md00230e","article-title":"New Insight into the Mode of Action of Vancomycin Dimers in Bacterial Cell Wall Synthesis","volume":"2","author":"Yoshida","year":"2011","journal-title":"Med. Chem. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"12681","DOI":"10.1002\/chem.201201211","article-title":"Elucidation of the Active Conformation of Vancomycin Dimers with Antibacterial Activity against Vancomycin-Resistant Bacteria","volume":"18","author":"Nakamura","year":"2012","journal-title":"Chem. Eur. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1039\/B613319C","article-title":"Synthesis of Rigidly-Linked Vancomycin Dimers and Their in Vivo Efficacy against Resistant Bacteria","volume":"3","author":"Lu","year":"2007","journal-title":"Chem. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41429-019-0164-1","article-title":"New Semisynthetic Teicoplanin Derivatives Have Comparable in Vitro Activity to That of Oritavancin against Clinical Isolates of VRE","volume":"72","author":"Nagy","year":"2019","journal-title":"J. Antibiot."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2174\/0929867013371716","article-title":"Glycopeptide Derivatives","volume":"8","author":"Malabarba","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"a026989","DOI":"10.1101\/cshperspect.a026989","article-title":"Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance","volume":"6","author":"Zeng","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1179\/joc.2005.17.6.593","article-title":"Antimicrobial Spectrum and Potency of Dalbavancin Tested Against Clinical Isolates from Europe and North America (2003): Initial Results from an International Surveillance Protocol","volume":"17","author":"Jones","year":"2005","journal-title":"J. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0213-005X(17)30028-9","article-title":"Actualizaci\u00f3n en la resistencia antibi\u00f3tica en Gram positivos","volume":"35","author":"Lozano","year":"2017","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2146\/ajhp110572","article-title":"Oritavancin: An Investigational Lipoglycopeptide Antibiotic","volume":"70","author":"Karaoui","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_60","first-page":"143","article-title":"Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment of Acute Bacterial Skin and Skin Structure Infections","volume":"43","author":"Rosenthal","year":"2018","journal-title":"Pharm. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"201704125","DOI":"10.1073\/pnas.1704125114","article-title":"Peripheral Modifications of [\u03a8[CH2NH]Tpg4] Vancomycin with Added Synergistic Mechanisms of Action Provide Durable and Potent Antibiotics","volume":"114","author":"Okano","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1089\/mdr.2019.0033","article-title":"In Vitro Synergistic Effect of Vancomycin Combined with Daptomycin Against Vancomycin-Resistant Enterococci","volume":"25","author":"Aktas","year":"2019","journal-title":"Microb. Drug Resist."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1099\/mic.0.000547","article-title":"Purified Citritin in Combination with Vancomycin Inhibits VRE in Vitro and in Vivo","volume":"163","author":"Queiroz","year":"2017","journal-title":"Microbiology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1128\/AAC.02790-13","article-title":"Activity of Daptomycin or Linezolid in Combination with Rifampin or Gentamicin against Biofilm-Forming Enterococcus faecalis or E. faecium in an In Vitro Pharmacodynamic Model Using Simulated Endocardial Vegetations and an In Vivo Survival Assay Using Galleria mellonella Larvae","volume":"58","author":"Luther","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10096-019-03801-x","article-title":"Role of Linezolid Combination Therapy for Serious Infections: Review of the Current Evidence","volume":"39","author":"Chen","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijantimicag.2019.04.010","article-title":"Efficacy of Oritavancin Alone and in Combination against Vancomycin-Susceptible and -Resistant Enterococci in an in-Vivo Galleria mellonella Survival Model","volume":"54","author":"Meyer","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.2147\/IDR.S219117","article-title":"Pharmacodynamics of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible and -Resistant Enterococci In Vitro and In Vivo of A Galleria mellonella Larval Infection Model","volume":"12","author":"Qi","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diagmicrobio.2013.07.012","article-title":"In Vitro Efficacy of Fosfomycin-Based Combinations against Clinical Vancomycin-Resistant Enterococcus Isolates","volume":"77","author":"Tang","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/jac\/dkr535","article-title":"In Vitro Efficacy of Fosfomycin-Containing Regimens against Methicillin-Resistant Staphylococcus aureus in Biofilms","volume":"67","author":"Tang","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/jac\/dkv007","article-title":"\u03b2-Lactam Combinations with Daptomycin Provide Synergy against Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium","volume":"70","author":"Smith","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.03006-15","article-title":"Oritavancin Combinations with \u03b2-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci","volume":"60","author":"Smith","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jac\/dkz010","article-title":"In Vitro Activity of Oritavancin Alone or in Combination against Vancomycin-Susceptible and -Resistant Enterococci","volume":"74","author":"Wu","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e01554-19","DOI":"10.1128\/AAC.01554-19","article-title":"Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens","volume":"64","author":"Mroue","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e00424-18","DOI":"10.1128\/AAC.00424-18","article-title":"In Vivo and in Vitro Effects of a ClpP-Activating Antibiotic against Vancomycin-Resistant Enterococci","volume":"62","author":"Gandt","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1021\/acsinfecdis.0c00319","article-title":"Attenuating the Selection of Vancomycin Resistance Among Enterococci through the Development of Peptide-Based Vancomycin Antagonists","volume":"6","author":"Mull","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1021\/acsinfecdis.9b00164","article-title":"Antagonizing Vancomycin Resistance in Enterococcus by Surface Localized Antimicrobial Display-Derived Peptides","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1021\/acsinfecdis.0c00016","article-title":"Combined Efficacy of an Antimicrobial Cationic Peptide Polymer with Conventional Antibiotics to Combat Multidrug-Resistant Pathogens","volume":"6","author":"Thappeta","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41429-018-0090-7","article-title":"Evaluation of LL-37 Antimicrobial Peptide Derivatives Alone and in Combination with Vancomycin against S","volume":"71","author":"Shurko","year":"2018","journal-title":"aureus. J. Antibiot."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.1002\/anie.202002727","article-title":"Vancomycin Resistance Is Overcome by Conjugation of Polycationic Peptides","volume":"59","author":"Domhan","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41586-019-1501-z","article-title":"Microbiota-Derived Lantibiotic Restores Resistance against Vancomycin-Resistant Enterococcus","volume":"572","author":"Kim","year":"2019","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2174\/138955707782795638","article-title":"Two-Peptide Lantibiotics: A Medical Perspective","volume":"7","author":"Lawton","year":"2007","journal-title":"MRMC"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkh387","article-title":"Mersacidin Eradicates Methicillin-Resistant Staphylococcus aureus (MRSA) in a Mouse Rhinitis Model","volume":"54","author":"Kruszewska","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"806230","DOI":"10.1155\/2012\/806230","article-title":"The Lantibiotic Lacticin 3147 Prevents Systemic Spread of Staphylococcus aureus in a Murine Infection Model","volume":"2012","author":"Piper","year":"2012","journal-title":"Int. J. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s00284-006-0632-2","article-title":"Pumilicin 4, A Novel Bacteriocin with Anti-MRSA and Anti-VRE Activity Produced by Newly Isolated Bacteria Bacillus pumilus Strain WAPB4","volume":"55","author":"Aunpad","year":"2007","journal-title":"Curr. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3389\/fmicb.2017.00774","article-title":"The Leaderless Bacteriocin Enterocin K1 Is Highly Potent against Enterococcus faecium: A Study on Structure, Target Spectrum and Receptor","volume":"8","author":"Ovchinnikov","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Phumisantiphong, U., Siripanichgon, K., Reamtong, O., and Diraphat, P. (2017). A Novel Bacteriocin from Enterococcus faecalis 478 Exhibits a Potent Activity against Vancomycin-Resistant Enterococci. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186415"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12223-016-0479-2","article-title":"Antimicrobial Peptide Isolated from Bacillus amyloliquefaciens K14 Revitalizes Its Use in Combinatorial Drug Therapy","volume":"62","author":"Regmi","year":"2017","journal-title":"Folia Microbiol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Montalb\u00e1n-L\u00f3pez, M., Cebri\u00e1n, R., Galera, R., Mingorance, L., Mart\u00edn-Platero, A.M., Valdivia, E., Mart\u00ednez-Bueno, M., and Maqueda, M. (2020). Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci. Antibiotics, 9.","DOI":"10.3390\/antibiotics9090567"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1089\/mdr.2012.0024","article-title":"Phage Endolysins with Broad Antimicrobial Activity against Enterococcus faecalis Clinical Strains","volume":"18","author":"Fernandes","year":"2012","journal-title":"Microb. Drug Resist."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e00555-19","DOI":"10.1128\/AEM.00555-19","article-title":"Bacteriophage \u03a6Ef11 ORF28 Endolysin, a Multifunctional Lytic Enzyme with Properties Distinct from All Other Identified Enterococcus faecalis Phage Endolysins","volume":"85","author":"Zhang","year":"2019","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Kim, S., Jin, J.-S., Choi, Y.-J., and Kim, J. (2020). LysSAP26, a New Recombinant Phage Endolysin with a Broad Spectrum Antibacterial Activity. Viruses, 12.","DOI":"10.3390\/v12111340"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00705-020-04861-7","article-title":"Intrinsic Resistance of Enterococcus faecalis Strains to \u03a6Ef11 Phage Endolysin Is Associated with the Presence of \u03a6Ef11 Prophage","volume":"166","author":"Zhang","year":"2020","journal-title":"Arch. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"G\u0142owacka-Rutkowska, A., Ulatowska, M., Empel, J., Kowalczyk, M., Boreczek, J., and \u0141obocka, M. (2020). A Kayvirus Distant Homolog of Staphylococcal Virulence Determinants and VISA Biomarker Is a Phage Lytic Enzyme. Viruses, 12.","DOI":"10.3390\/v12030292"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/IAI.70.1.204-210.2002","article-title":"Bacteriophage Therapy Rescues Mice Bacteremic from a Clinical Isolate of Vancomycin-Resistant Enterococcus faecium","volume":"70","author":"Biswas","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"32157","DOI":"10.3402\/jom.v8.32157","article-title":"Phage Therapy against Enterococcus faecalis in Dental Root Canals","volume":"8","author":"Khalifa","year":"2016","journal-title":"J. Oral Microbiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.resmic.2018.04.008","article-title":"Combined Bacteriophages and Antibiotics as an Efficient Therapy against VRE Enterococcus faecalis in a Mouse Model","volume":"169","author":"Gelman","year":"2018","journal-title":"Res. Microbiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fmicb.2018.00326","article-title":"Defeating Antibiotic- and Phage-Resistant Enterococcus faecalis Using a Phage Cocktail in Vitro and in a Clot Model","volume":"9","author":"Khalifa","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Shlezinger, M., Coppenhagen-Glazer, S., Gelman, D., Beyth, N., and Hazan, R. (2019). Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin. Viruses, 11.","DOI":"10.3390\/v11100954"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"G\u00f3rski, A., Mi\u0119dzybrodzki, R., \u0141obocka, M., G\u0142owacka-Rutkowska, A., Bednarek, A., Borysowski, J., Jo\u0144czyk-Matysiak, E., \u0141usiak-Szelachowska, M., Weber-D\u0105browska, B., and Bagi\u0144ska, N. (2018). Phage Therapy: What Have We Learned?. Viruses, 10.","DOI":"10.3390\/v10060288"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.addr.2013.07.011","article-title":"Nanotechnology as a Therapeutic Tool to Combat Microbial Resistance","volume":"65","author":"Pelgrift","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/jid.2012.399","article-title":"Antimicrobial and Anti-Inflammatory Activity of Chitosan-Alginate Nanoparticles: A Targeted Therapy for Cutaneous Pathogens","volume":"133","author":"Friedman","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1021\/acs.nanolett.8b01000","article-title":"Block Copolymer Nanoparticles Remove Biofilms of Drug-Resistant Gram-Positive Bacteria by Nanoscale Bacterial Debridement","volume":"18","author":"Li","year":"2018","journal-title":"Nano Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1039\/C9BM01050E","article-title":"Construction, Mechanism, and Antibacterial Resistance Insight into Polypeptide-Based Nanoparticles","volume":"7","author":"Zhen","year":"2019","journal-title":"Biomater. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrmicro3155","article-title":"Ribosome-Targeting Antibiotics and Mechanisms of Bacterial Resistance","volume":"12","author":"Wilson","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1139\/cjm-2019-0309","article-title":"Renaissance of Vancomycin: Approaches for Breaking Antibiotic Resistance in Multidrug-Resistant Bacteria","volume":"66","author":"Kleist","year":"2020","journal-title":"Can. J. Microbiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3389\/fmicb.2018.01175","article-title":"Iterative Chemical Engineering of Vancomycin Leads to Novel Vancomycin Analogs with a High in Vitro Therapeutic Index","volume":"9","author":"Mishra","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/S0960-894X(02)00664-9","article-title":"Novel Semi-Synthetic Glycopeptide Antibiotics Active against Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE): Doubly-Modified Water-Soluble Derivatives of Chloroorienticin B","volume":"12","author":"Yoshida","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/cb300007j","article-title":"Redesign of Glycopeptide Antibiotics\u2014Back to the Future","volume":"7","author":"James","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.bmcl.2004.11.014","article-title":"Design and Synthesis of Macrocycles Active against Vancomycin-Resistant Enterococci (VRE): The Interplay between d-Ala-d-Lac Binding and Hydrophobic Effect","volume":"15","author":"Ma","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_110","first-page":"127","article-title":"Telavancin (Vibativ), a New Option for the Treatment of Gram-Positive Infections","volume":"36","author":"Plotkin","year":"2011","journal-title":"Pharm. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/ja.2009.66","article-title":"Synthesis and Combinational Antibacterial Study of 5\u2033-Modified Neomycin","volume":"62","author":"Zhang","year":"2009","journal-title":"J. Antibiot."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"488","DOI":"10.24272\/j.issn.2095-8137.2019.062","article-title":"Antimicrobial Peptides: New Hope in the War against Multidrug Resistance","volume":"40","author":"Mwangi","year":"2019","journal-title":"Zool. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijantimicag.2010.04.008","article-title":"The Antimicrobial Peptide Ci-MAM-A24 Is Highly Active against Multidrug-Resistant and Anaerobic Bacteria Pathogenic for Humans","volume":"36","author":"Fedders","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0022034516679973","article-title":"Antimicrobial Peptides","volume":"96","author":"Bechinger","year":"2017","journal-title":"J. Dent. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.micpath.2019.01.002","article-title":"Bacteriocins: Classification, Synthesis, Mechanism of Action and Resistance Development in Food Spoilage Causing Bacteria","volume":"128","author":"Kumariya","year":"2019","journal-title":"Microb. Pathog."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/mmi.14419","article-title":"Roseocin, a Novel Two-component Lantibiotic from an Actinomycete","volume":"113","author":"Singh","year":"2020","journal-title":"Mol. Microbiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jmii.2013.05.004","article-title":"Antimicrobial Activity of a UV-Stable Bacteriocin-like Inhibitory Substance (BLIS) Produced by Enterococcus faecium Strain DSH20 against Vancomycin-Resistant Enterococcus (VRE) Strains","volume":"47","author":"Shokri","year":"2014","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1128\/AAC.50.4.1202-1212.2006","article-title":"Bac 32, a Novel Bacteriocin Widely Disseminated among Clinical Isolates of Enterococcus faecium","volume":"50","author":"Inoue","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1128\/AEM.00934-06","article-title":"Genetic Analysis of Bacteriocin 43 of Vancomycin-Resistant Enterococcus faecium","volume":"72","author":"Todokoro","year":"2006","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1128\/AEM.00299-15","article-title":"Pseudomycoicidin, a Class II Lantibiotic from Bacillus pseudomycoides","volume":"81","author":"Dischinger","year":"2015","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1021\/acschembio.5b00584","article-title":"Characterization of Sviceucin from Streptomyces Provides Insight into Enzyme Exchangeability and Disulfide Bond Formation in Lasso Peptides","volume":"10","author":"Li","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1021\/acs.accounts.5b00156","article-title":"Lasso Peptides: An Intriguing Class of Bacterial Natural Products","volume":"48","author":"Hegemann","year":"2015","journal-title":"Acc. Chem. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/cid\/ciz222","article-title":"Successful Treatment of Antibiotic-Resistant, Poly-Microbial Bone Infection with Bacteriophages and Antibiotics Combination","volume":"69","author":"Gelman","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Leitner, L., Sybesma, W., Chanishvili, N., Goderdzishvili, M., Chkhotua, A., Ujmajuridze, A., Schneider, M.P., Sartori, A., Mehnert, U., and Bachmann, L.M. (2017). Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial. BMC Urol., 17.","DOI":"10.1186\/s12894-017-0283-6"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","article-title":"Oral Phage Therapy of Acute Bacterial Diarrhea with Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh","volume":"4","author":"Sarker","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2672.2012.05361.x","article-title":"Bacteriophage Control of Vancomycin-Resistant Enterococci in Cattle Compost","volume":"113","author":"Otawa","year":"2012","journal-title":"J. Appl. Microbiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijantimicag.2019.06.007","article-title":"Lytic Bacteriophages against Multidrug-Resistant Staphylococcus aureus, Enterococcus faecalis and Escherichia coli Isolates from Orthopaedic Implant-Associated Infections","volume":"54","author":"Barros","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1574-6968.2007.00996.x","article-title":"Isolation and Characterization of a Novel Enterococcus faecalis Bacteriophage \u03a6EF24C as a Therapeutic Candidate","volume":"278","author":"Uchiyama","year":"2008","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Sofy, A.R., Abd El Haliem, N.F., Refaey, E.E., and Hmed, A.A. (2020). Polyvalent Phage CoNShP-3 as a Natural Antimicrobial Agent Showing Lytic and Antibiofilm Activities against Antibiotic-Resistant Coagulase-Negative Staphylococci Strains. Foods, 9.","DOI":"10.3390\/foods9050673"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e00066-18","DOI":"10.1128\/CMR.00066-18","article-title":"Phage Therapy in the Postantibiotic Era","volume":"32","author":"Altamirano","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-60327-164-6_23","article-title":"Generalized Transduction","volume":"Volume 501","author":"Clokie","year":"2009","journal-title":"Bacteriophages"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3389\/fmicb.2015.01271","article-title":"On-Demand Isolation of Bacteriophages Against Drug-Resistant Bacteria for Personalized Phage Therapy","volume":"6","author":"Mattila","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","article-title":"Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria","volume":"25","author":"Kortright","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.chom.2020.06.002","article-title":"The Spatial Heterogeneity of the Gut Limits Predation and Fosters Coexistence of Bacteria and Bacteriophages","volume":"28","author":"Chaffringeon","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","article-title":"Safety of Bacteriophage Therapy in Severe Staphylococcus aureus Infection","volume":"5","author":"Fabijan","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00284-016-1166-x","article-title":"Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages","volume":"74","author":"Cisek","year":"2017","journal-title":"Curr. Microbiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1073\/pnas.1714658115","article-title":"Cross-Genus Rebooting of Custom-Made, Synthetic Bacteriophage Genomes in L-Form Bacteria","volume":"115","author":"Kilcher","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ijbiomac.2020.05.197","article-title":"Antibacterial, Anticoagulant and Cytotoxic Evaluation of Biocompatible Nanocomposite of Chitosan Loaded Green Synthesized Bioinspired Silver Nanoparticles","volume":"160","author":"Asghar","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1128\/AAC.01830-09","article-title":"Silver Coordination Polymers for Prevention of Implant Infection: Thiol Interaction, Impact on Respiratory Chain Enzymes, and Hydroxyl Radical Induction","volume":"54","author":"Gordon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11274-009-0211-3","article-title":"Bactericidal Effect of Silver Nanoparticles against Multidrug-Resistant Bacteria","volume":"26","author":"Lara","year":"2010","journal-title":"World J. Microbiol. Biotechnol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.2147\/IJN.S272734","article-title":"Therapeutic Potential Assessment of Green Synthesized Zinc Oxide Nanoparticles Derived from Fennel Seeds Extract","volume":"15","author":"AlSalhi","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3389\/fmicb.2018.02207","article-title":"Efficiency of Biosynthesized Silver and Zinc Nanoparticles Against Multi-Drug Resistant Pathogens","volume":"9","author":"Punjabi","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e31302","DOI":"10.5812\/jjm.31302","article-title":"Enhancing the Anti-Enterococci Activity of Different Antibiotics by Combining with Metal Oxide Nanoparticles","volume":"9","author":"Iram","year":"2016","journal-title":"Jundishapur J. Microbiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1021\/am507919m","article-title":"Potent Antibacterial Nanoparticles for Pathogenic Bacteria","volume":"7","author":"Lai","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/nnm-2017-0380","article-title":"Antibacterial Gold Nanoparticle-Based Photothermal Killing of Vancomycin-Resistant Bacteria","volume":"13","author":"Wang","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"105103","DOI":"10.1088\/0957-4484\/21\/10\/105103","article-title":"Nanoconjugated Vancomycin: New Opportunities for the Development of Anti-VRSA Agents","volume":"21","author":"Chakraborty","year":"2010","journal-title":"Nanotechnology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3109\/10837450.2013.846375","article-title":"Optimization of Particle Size and Encapsulation Efficiency of Vancomycin Nanoparticles by Response Surface Methodology","volume":"19","author":"Honary","year":"2014","journal-title":"Pharm. Dev. Technol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nature18849","article-title":"Interactions between the Microbiota and Pathogenic Bacteria in the Gut","volume":"535","author":"Sperandio","year":"2016","journal-title":"Nature"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/9\/1116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:00:32Z","timestamp":1760166032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/9\/1116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":148,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["antibiotics10091116"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10091116","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}